A Phase 3 interventional study of Lumateperone and Placebo in Bipolar Disorder, Manic, sponsored by Intra-Cellular Therapies, Inc.. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Intra-Cellular Therapies, Inc. · Phase 3, Interventional, and Treatment
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
The study will be conducted in 3 phases:
1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.
This study's enrollment of 354 is above the median of 64 across 1,223 interventional studies indexed under Bipolar Disorder.
Browse Bipolar Disorder studies →Intra-Cellular Therapies, Inc. is the lead sponsor of 40 studies on the registry; 12 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 10 (43%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Has a current primary DSM 5 psychiatric diagnosis other than bipolar disorder. These include:
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of his/her participation in the study or
Lumateperone 42 mg capsules
Drug: Lumateperone
Matching placebo
Drug: Placebo
Lumateperone 42 mg capsules administered orally, once daily
Matching capsules administered orally, once daily
Young Mania Rating Scale (YMRS)
The YMRS is an 11-item, clinician-administered mania rating scale designed to assess the severity of manic symptoms. Four of the YMRS items are rated on a 0 to 8 scale, with the remaining 7 items rated on a 0 to 4 scale. The total score ranges from 0 to 60 with a higher score indicating increased severity of manic symptoms.
Time frame: Week 3
Clinical Global Impression Scale-Severity (CGI-S)
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Week 3
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intra-Cellular Therapies, Inc.